Answers are grounded in this paper and cite their sources.
Summary Bioactive‐LH (B‐LH) was measured in plasma by in‐vitro bioassay and immunoactive‐LH (I‐LH) by immunoassay at 10 min intervals for 6 h in five men after standard chemotherapy for Hodgkin's disease. Eleven normal men acted as controls. Follicle‐stimulating hormone (FSH) was markedly raised in the treated patients (mean ± SEM; 12.8 ± 2.8 vs. 2.7 ± 0.4 IU 1 ‐1 , P >0.006) reflecting damage to the germinal epithelium. Bioactive (27.4 ± 2.8 vs. 12.9 ± 1.3 IU 1 ‐1 ) and I‐LH (9.6 ± 2.0 vs. 4.9 ± 0.4 IU 1 ‐1 ) were elevated ( P >0.006) in the patient group whilst testosterone levels (24.0 3.8 vs. 19.6 2.4 nmol 1 ‐1 ) were normal. The testosterone I‐LH ratio, a putative index of Leydig cell dysfunction, was negatively correlated with FSH levels (r=‐0.85, P >0.02). Bioactive and I‐LH pulse peak amplitude were elevated, as were pulse maxima ( P >0.05). In contrast, B‐LH pulse frequency was similar between the patients (2 pulses per 6 h) and controls (median 2, range 1–3 pulses per 6 h) as was the I‐LH pulse frequency (median 2, 1–2 pulses per 6 h in both groups). The mean B:I LH ratios were similar (2.94 ± 0.09 vs. 2.63 ± 0.14) in both groups, although the inter‐pulse B:I ratio was increased ( P >0.007) in the patient group. It is concluded that normal levels of testosterone are maintained in men with chemotherapy‐induced damage to the germinal epithelium by a resetting of the hypothalamic‐pituitary unit such that LH pulse amplitude but not the pulse frequency is increased markedly. The mean biopotency of LH remained unchanged although the inter‐pulse B:I LH was increased.
No takes yet. Share an insight, caveat, or question.
Talbot et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: